B
31.05
-0.37 (-1.18%)
| Previous Close | 31.42 |
| Open | 31.42 |
| Volume | 481,302 |
| Avg. Volume (3M) | 771,478 |
| Market Cap | 1,366,964,736 |
| Price / Sales | 15.10 |
| Price / Book | 4.54 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -101.62% |
| Operating Margin (TTM) | -105.69% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | 36.40% |
| Total Debt/Equity (MRQ) | 2.22% |
| Current Ratio (MRQ) | 15.88 |
| Operating Cash Flow (TTM) | -56.10 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Beta Bionics, Inc. | Bullish | - |
AIStockmoo Score
0.2
| Analyst Consensus | 1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.20 |
|
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 6.51% |
| % Held by Institutions | 98.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Goldman Sachs, 6.28%) | Buy |
| Median | 32.00 (3.06%) | |
| Low | 31.00 (Stifel, -0.16%) | Buy |
| Average | 32.00 (3.06%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 26.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 29 Oct 2025 | 33.00 (6.28%) | Buy | 26.79 |
| 01 Oct 2025 | 26.00 (-16.26%) | Buy | 20.21 | |
| Piper Sandler | 29 Oct 2025 | 32.00 (3.06%) | Buy | 26.79 |
| Stifel | 29 Oct 2025 | 31.00 (-0.16%) | Buy | 26.79 |
| 21 Oct 2025 | 26.00 (-16.26%) | Buy | 20.98 | |
| Truist Securities | 29 Oct 2025 | 32.00 (3.06%) | Buy | 26.79 |
| 22 Sep 2025 | 28.00 (-9.82%) | Buy | 22.90 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEIDER STEPHEN | - | 28.44 | -1,427 | -40,584 |
| LEZACK ADAM | - | 29.53 | -1,406 | -41,519 |
| MENSINGER MIKE | - | 28.44 | -1,063 | -30,232 |
| PALASIS MARIA | - | 29.53 | -1,406 | -41,519 |
| SAINT SEAN | - | 28.44 | -3,278 | -93,226 |
| Aggregate Net Quantity | -8,580 | |||
| Aggregate Net Value ($) | -247,080 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 28.88 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FEIDER STEPHEN | Officer | 02 Dec 2025 | Sell (-) | 1,427 | 28.44 | 40,584 |
| SAINT SEAN | Officer | 02 Dec 2025 | Sell (-) | 3,278 | 28.44 | 93,226 |
| MENSINGER MIKE | Officer | 02 Dec 2025 | Sell (-) | 1,063 | 28.44 | 30,232 |
| PALASIS MARIA | Director | 01 Dec 2025 | Automatic sell (-) | 1,406 | 29.53 | 41,519 |
| LEZACK ADAM | Director | 01 Dec 2025 | Automatic sell (-) | 1,406 | 29.53 | 41,519 |
| Date | Type | Details |
|---|---|---|
| 03 Nov 2025 | Announcement | Beta Bionics Announces Participation at Upcoming Investor Conferences |
| 28 Oct 2025 | Announcement | Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance |
| 09 Oct 2025 | Announcement | Beta Bionics to Announce Third Quarter 2025 Financial Results on October 28, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |